Maqola

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia

Jeffrey M. PernicaDivision of Infectious Diseases, Department of Pediatrics, McMaster University, Hamilton, Ontario, CanadaStuart HarmanDivision of Emergency Medicine, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, CanadaApril KamDivision of Emergency Medicine, Department of Pediatrics, McMaster University, Hamilton, Ontario, CanadaRedjana CarciumaruDepartment of Pediatrics, McMaster University, Hamilton, Ontario, CanadaThuva VanniyasingamBiostiatistics Unit, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, CanadaTyrus CrawfordChildren’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, CanadaDale DalgleishChildren’s Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, CanadaSarah KhanDivision of Infectious Diseases, Department of Pediatrics, McMaster University, Hamilton, Ontario, CanadaRobert SlingerDepartment of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, CanadaMartha FulfordDivision of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, CanadaCheryl MainDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, CanadaMarek SmiejaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, CanadaLehana ThabaneDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, CanadaMark LoebDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

2021en

ABI

Annotatsiya

Importance: Community-acquired pneumonia (CAP) is a common occurrence in childhood; consequently, evidence-based recommendations for its treatment are required. Objective: To determine whether 5 days of high-dose amoxicillin for CAP was associated with noninferior rates of clinical cure compared with 10 days of high-dose amoxicillin. Design, Setting, and Participants: The SAFER (Short-Course Antimicrobial Therapy for Pediatric Respiratory Infections) study was a 2-center, parallel-group, noninferiority randomized clinical trial consisting of a single-center pilot study from December 1, 2012, to March 31, 2014, and the follow-up main study from August 1, 2016, to December 31, 2019 at the emergency departments of McMaster Children's Hospital and the Children's Hospital of Eastern Ontario. Research staff, participants, and outcome assessors were blinded to treatment allocation. Eligible children were aged 6 months to 10 years and had fever within 48 hours, respiratory symptoms, chest radiography findings consistent with pneumonia as per the emergency department physician, and a primary diagnosis of pneumonia. Children were excluded if they required hospitalization, had comorbidities that would predispose them to severe disease and/or pneumonia of unusual origin, or had previous β-lactam antibiotic therapy. Data were analyzed from March 1 to July 8, 2020. Interventions: Five days of high-dose amoxicillin therapy followed by 5 days of placebo (intervention group) vs 5 days of high-dose amoxicillin followed by a different formulation of 5 days of high-dose amoxicillin (control group). Main Outcomes and Measures: Clinical cure at 14 to 21 days. Results: Among the 281 participants, the median age was 2.6 (interquartile range, 1.6-4.9) years (160 boys [57.7%] of 279 with sex listed). Clinical cure was observed in 101 of 114 children (88.6%) in the intervention group and in 99 of 109 (90.8%) in the control group in per-protocol analysis (risk difference, -0.016; 97.5% confidence limit, -0.087). Clinical cure at 14 to 21 days was observed in 108 of 126 (85.7%) in the intervention group and in 106 of 126 (84.1%) in the control group in the intention-to-treat analysis (risk difference, 0.023; 97.5% confidence limit, -0.061). Conclusions and Relevance: Short-course antibiotic therapy appeared to be comparable to standard care for the treatment of previously healthy children with CAP not requiring hospitalization. Clinical practice guidelines should consider recommending 5 days of amoxicillin for pediatric pneumonia management in accordance with antimicrobial stewardship principles. Trial Registration: ClinicalTrials.gov Identifier: NCT02380352.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1001/jamapediatrics.2020.6735

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar